#Contract API Manufacturer

[akumspharmaceuticals]

API intermediates manufacturer in India | Akums

Among numerous contract API manufacturing pharma companies in India, Akums Drugs & Pharmaceuticals Ltd is an unrivaled brand name.

[octanexlabsin]

Driving Excellence in Chemical Innovation: Our expertise spans Pharma, Agro, Fine and Specialty Chemicals, CRO, and CDMO sectors, where we provide tailored synthesis solutions. Through strategic partnerships in custom development and CRAMS, we ensure the highest quality standards. We are dedicated to enriching lives by combining premium research, production, and marketing.

[chemxpert]

Contract Manufacturing: Driving Growth and Efficiency in Pharma

Contract manufacturing has become a cornerstone of the pharmaceutical industry, allowing companies to streamline operations, reduce costs, and focus on core competencies like research and development. This model is pivotal for ensuring that medicines, including complex compounds like Clobetasol, Dextromethorphan Hydrobromide Monohydrate, and Dorzolamide, reach global markets efficiently. This blog explores the role of contract manufacturing in pharma, its benefits, and its implications for the industry.

[cdmoservices]

Pharma API Manufacturing Sites & Capabilities | CDMO Company | CRO | Aurigene Pharmaceutical Services

We operate 8 API manufacturing sites. Each of these sites has a dedicated facilities associated with capacity, capability, desired market, & appropriate regulatory status.

To know more:https://www.aurigeneservices.com/services/manufacturing/sites-and-capabilities

[sauravchemicals]

Unlock innovation with our Contract API Manufacturing services!

Discover excellence in pharmaceutical solutions with Saurav Chemicals. As a leading player in Contract API Manufacturing, we specialize in delivering high-quality active pharmaceutical ingredients tailored to meet diverse industry needs. Explore our API product offerings and experience innovation at its finest.

[market-insider]

ontract Manufacturing in the Generic Pharma Sector: Trends and Analysis

The global generic pharmaceuticals contract manufacturing market size is expected to reach USD 106.9 billion by 2030, registering a CAGR of 5.8% over the forecast period, according to a new report by Grand View Research, Inc. Cost-saving and time-saving benefits associated with the implementation of outsourcing is responsible for driving the industry. A significant number of people globally suffer from chronic diseases. For instance, the CDC states that 6 in 10 adults in the U.S. suffer from at least one chronic disease and 4 in 10 adults suffer from two or more chronic diseases. Chronic diseases are required to be treated for a long time. The high cost of medicines is increasing the demand for cost-effective generic drugs for the treatment of chronic diseases.

Generic Pharmaceuticals Contract Manufacturing Market Report Highlights

The branded generics segment held the largest share in 2021due to the preference for branded generics among physicians. Some branded generic manufacturers offer benefits and gifts to physicians for boosting their product sales. This further contributes to the demand for branded generic manufacturing in the market

The API product segment held the largest share in 2021. The growing demand for generic drugs is supporting the demand for generic API contract manufacturing

The parenteral route of administration segment is expected to grow at the fastest CAGR over the forecast period due to the bioavailability of parenteral drugs over other formulations

The oncology segment is expected to register the fastest CAGRfrom 2022 to 2030 owing to the high cost of cancer drugs contributing to the demand for cost-effective generic medicines

Asia Pacific is expected to record the highest CAGR over the forecast period mainly due to the low cost of generic drug manufacturing

Gain deeper insights on the market and receive your free copy with TOC now @: Generic Pharmaceuticals Contract Manufacturing Market Report

This is expected to support the industry's growth post-pandemic. There is an improvement in the regulatory approval of generic drugs. For instance, in 2021, the FDA approved 93 generic drugs, and by October 2022, the regulatory authority approved over 95 generic drugs. Such improvements are expected to have a positive impact on the manufacturing of generic drugs and; thus, support the industry growth. The Japanese government is constantly trying to improve the generic pharmaceuticals market in the country. The government is also taking measures to improve the supply of generics in the country and is also encouraging medical institutes to promote the use of generic drugs.

This is expected to improve CMO activities for generics in the coming years. Global spending on medicines is also on the rise. According to the data provided in a report published by IQVIA in April 2021, global spending on medicine is expected to increase in the next 4-5 years. The report states that global spending on medicine accounted for USD 1, 265 billion in 2020 and is going to reach USD 1,580-1,610 billion by 2025. This is also expected to improve the demand for generic drugs owing to their cost efficiency, thereby supporting the industry in growth.

[neha24blog]

High Potency API Contract Manufacturing Market Outlook On The Basis Of Product Type, Application, Synthesis, Dosage Form, Region And Forecast to 2030: Grand View Research Inc.

San Francisco, 10 Aug 2023: The Report High Potency API Contract Manufacturing Market Size, Share & Trends Analysis Report By Product Type (Innovative, Generic), By Dosage Form (Injectable, Creams), By Application, By Synthesis, And Segment Forecasts, 2022 – 2030 The global high potency API contract manufacturing market size is expected to reach USD 14.65 billion by 2030, registering a CAGR of…

[mysticalcrowntyphoon]

The Pharma Third Party Manufacturing site should be capable of assisting in early-stage process development for both API and finished drug products.

Table of Content

Active Pharmaceutical Ingredient  (API)

Finished drug product (FDP)

Pharmaceutical third-party manufacturing

Akums Drugs and Pharmaceuticals ltd.

 Active Pharmaceutical Ingredient (API)

API stands for "Active Pharmaceutical Ingredient," is the part of a drug that produces the intended pharmacological effect and is responsible for the therapeutic activity of a medication.

Simply, the API is the chemical substance that is responsible for treating a specific condition or disease. For example, in a painkiller medication, the API would be the chemical that actually reduces pain.

Pharmaceutical companies use APIs to create medications, which are then formulated into different dosage forms, such as tablets, capsules, injections, or creams. The APIs used in medications are subject to strict quality standards and regulatory requirements, ensuring that they are safe and effective for human use.

Finished drug product (FDP)

 A finished drug product (FDP) is a medication that has completed the manufacturing process and is ready to be dispensed to patients.A finished drug product typically consists of the active pharmaceutical ingredient (API), which is the part of the medication that produces the intended pharmacological effect, as well as other inactive ingredients, which may include fillers, binders, and coatings.

The formulation of an FDP can vary depending on the intended route of administration, dosage strength, and other factors. FDPs can be available in different dosage forms, such as tablets, capsules, injections, or creams, and can be marketed under different brand names by different pharmaceutical companies.

Before a finished drug product can be marketed and sold to patients, it must undergo extensive testing and regulatory approval by government agencies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These agencies evaluate the safety, efficacy, and quality of the FDP to ensure that it meets the necessary standards for human use.

Pharmaceutical third-party manufacturing

A pharmaceutical third-party manufacturing site that specializes in contract manufacturing can provide services to assist in the early-stage process development for both active pharmaceutical ingredients (APIs) and finished drug products (FDPs).

 These services may include:

·API process development: The site can offer expertise in developing the chemical process for synthesizing the API, optimizing yields, and minimizing impurities. They may also provide analytical services to characterize the API and ensure its purity and potency.

·Formulation development: The site can assist in the formulation of the FDP, including the selection of appropriate excipients, dosage form, and route of administration. They can also help optimize the drug product for bioavailability, stability, and other factors.

·Scale-up and validation: Once the process and formulation have been developed, the site can help scale up the manufacturing process and conduct validation studies to ensure that the process is robust and reproducible.

·Regulatory support: The site can provide support in preparing regulatory submissions, including documentation of the manufacturing process, quality control testing, and stability studies.

Akums Drugs and Pharmaceuticals ltd.

Akums Drugs and Pharmaceuticals ltd. is a pharmaceutical third-party manufacturing site that offers a wide range of services to support the development of APIs and FDPs, from early-stage process development to commercial-scale production. By leveraging their expertise, companies accelerate their drug development programs and bring new therapies to market more efficiently.

Key Takeaways

·A pharmaceutical third-party manufacturing site or contract manufacturing can provide services to assist in the early-stage process development for both active pharmaceutical ingredients (APIs) and finished drug products (FDPs).

· Akums Drugs and Pharmaceuticals ltd. is a pharmaceutical third-party manufacturing site that offers a wide range of services to support the development of APIs and FDPs,

[justinspoliticalcorner]

Lori Ann Larocco at CNBC:

Billions in trade came to a screeching halt at U.S. East Coast and Gulf Coast ports after members of the International Longshoremen’s Association (ILA) began walking off the job after 12:01 a.m. ET on October 1. The ILA is North America’s largest longshoremen’s union, with roughly 50,000 of its 85,000 members making good on the threat to strike at 14 major ports subject to a just-expired master contract with the United States Maritime Alliance (USMX), and picketing workers beginning to appear at ports. The union and port ownership group failed to reach agreement by midnight on a new contract in a protracted battle over wage increases and use of automation. In a last-ditch effort on Monday to avert a strike that will cause significant harm to the U.S. economy if it is lengthy — at least hundreds of millions of dollars a day at the largest ports like New York/New Jersey — the USMX offered a nearly 50% wage hike over six years, but that was rejected by the ILA, according to a source close to the negotiations. The port ownership group said it hoped the offer would lead to a resumption of collective bargaining.

The 14 ports where preparations for a strike have been underway are Boston, New York/New Jersey, Philadelphia, Wilmington, North Carolina, Baltimore, Norfolk, Charleston, Savannah, Jacksonville, Tampa, Miami, New Orleans, Mobile, and Houston. New York Governor Kathy Hochul said in a statement issued shortly after midnight that “the first large-scale eastern dockworker strike in 47 years began at ports from Maine to Texas, including at the Port Authority of New York and New Jersey. In preparation for this moment, New York has been working around the clock to ensure that our grocery stores and medical facilities have the essential products they need.” Rhetoric from ILA leadership has been aggressive in the weeks leading up to the strike, with ILA president Harold Daggett, who was a union member the last time it went out on strike in 1977, telling rank-and-file members — who unanimously voted to authorize a strike — in a recent video message, “We’ll crush them.” 

[...] The most significant issues would be faced by food and automobile industries, Kamins said, as they rely especially heavily on the ports that will be shut down. While a surge in inflation is highly unlikely even with a longer strike, even a modest reacceleration could create uncertainty and force the Federal Reserve to be more cautious about lowering interest rates, which would weigh on the overall outlook for job growth and investment. A one-week strike could cost the U.S. economy $3.78 billion, according to an analysis by The Conference Board, and cause supply chain slowdowns through mid-November. In all, the ports threatened with strikes handle $3 trillion annually in U.S. annual international trade.

Many industries are preparing for major repercussions. Noushin Shamsili, CEO and president of Nuco Logistics, which specializes in pharmaceutical imports and exports, said the strike comes at a critical time for inventory replenishment for the pharma sector. “Almost all of this industry is just on time,” said Shamsili. “Raw materials are being brought in to complete drug manufacturing. Medical supplies for clinics and hospitals are on these vessels. For a while importers did not bring in a lot of cargo because they were overflowing with supplies post-Covid. Now they have started reordering medical devices, gloves, syringes, and tubing.” Shamsili also said the East Coast ports are a gateway for generic medicine made in India. Approximately 48% of the active pharmaceutical ingredients used in the U.S. are being imported from India. Without these APIs, medications cannot be produced. APIs are also manufactured in Europe, which also use the East Coast ports as U.S. points of entry.

[...] The Biden administration finds itself in a delicate political moment, with the presidential election one month away and President Biden vowing he will not use existing labor law to force union workers back on the job, which is within his powers under the Taft-Hartley Act. The Taft-Hartley Act, passed in 1947, was a revision of U.S. law governing labor relations and union activity that granted a U.S. president the power to suspend a strike for an 80-day “cooling off period” in cases where “national health or safety” are at risk. 

Today begins the strike along East Coast and Gulf Coast ports after International Longshoremen’s Association (ILA) members walked off their jobs.

This strike, depending on how long it lasts, could have a major impact on the elections and the economy.

[queenlua]

"Vulkan is weird— but it's weird in a way that makes a certain sort of horrifying machine sense. Every Vulkan call involves passing in one or two huge structures which are themselves a forest of other huge structures, and every structure and sub-structure begins with a little protocol header explaining what it is and how big it is. Before you allocate memory you have to fill out a structure to get back a structure that tells you what structure you're supposed to structure your memory allocation request in. None of it makes any sense— unless you've designed a programming language before, in which case everything you're reading jumps out to you as "oh, this is contrived like this because it's designed to be easy to bind to from languages with weird memory-management techniques" "this is a way of designing a forward-compatible ABI while making no assumptions about programming language" etc. The docs are written in a sort of alien English that fosters no understanding— but it's also written exactly the way a hardware implementor would want in order to remove all ambiguity about what a function call does. In short, Vulkan is not for you. It is a byzantine contract between hardware manufacturers and middleware providers, and people like… well, me, are just not part of the transaction.

Khronos did not forget about you and me. They just made a judgement, and this actually does make a sort of sense, that they were never going to design the perfectly ergonomic developer API anyway, so it would be better to not even try and instead make it as easy as possible for the perfectly ergonomic API to be written on top, as a library. Khronos thought within a few years of Vulkan being released there would be a bunch of high-quality open source wrapper libraries that people would use instead of Vulkan directly. These libraries basically did not materialize. It turns out writing software is work and open source projects do not materialize just because people would like them to."

[akumspharmaceuticals]

The Vital Role of Raw Material API in Pharmaceutical Manufacturing

In the world of pharmaceuticals, there is more to the pill you pop than meets the eye. Behind every medicine that makes its way to your local pharmacy or healthcare provider, there is a complex process that begins with raw materials and relies heavily on API (Active Pharmaceutical Ingredient) contract manufacturers. In this blog, we will explore the vital role of raw material APIs in pharmaceutical manufacturing and shed light on the unsung heroes - API contract manufacturers.

Understanding Raw Material APIs

Before we go into the nitty-gritty, let us break down the basics. Active Pharmaceutical Ingredients, or APIs, are the essential components in medications that produce the intended therapeutic effect. In simpler terms, they are the superheroes that make your medicine work. These APIs can be derived from natural sources or synthesized through chemical processes.

The Importance of Quality Raw Materials

Imagine baking a cake with subpar ingredients – the end result would likely be a disappointment. Similarly, in pharmaceutical manufacturing, the quality of raw materials, especially APIs, is of utmost importance. The efficacy and safety of the final medicine depend on the purity and consistency of these raw materials.

Quality control measures start right from the sourcing of raw materials. Pharmaceutical brands therefore rely on contract API manufacturers to rigorously assess and select suppliers who adhere to strict quality standards. This ensures that the APIs meet the required specifications, providing a foundation for the production of safe and effective medications.

API Contract Manufacturers: The Unsung Heroes

Now, let us shine a spotlight on the behind-the-scenes players - API contract manufacturers. These are specialized companies that pharmaceutical firms enlist to produce APIs on their behalf. Think of them as the secret ingredient suppliers for pharmaceutical companies.

One key advantage of outsourcing API manufacturing to contract manufacturers is expertise. These companies often specialize in specific types of APIs, allowing them to hone their skills and stay abreast of the latest technologies. This specialization translates into higher efficiency and quality in the production process.

Cost-effectiveness is another significant factor. Setting up and maintaining API manufacturing facilities requires a substantial investment in infrastructure, equipment, and skilled personnel. By outsourcing to API contract manufacturers, pharmaceutical companies can reduce overhead costs and focus on their core competencies – drug development and marketing.

Flexibility and scalability are also noteworthy benefits. The pharmaceutical industry is dynamic, with fluctuating demand for different medications. API contract manufacturers offer the flexibility to scale production up or down based on market demands, enabling pharmaceutical companies to respond swiftly to changing conditions.

Ensuring Regulatory Compliance

In the pharmaceutical world, regulations are stringent, and compliance is non-negotiable. API contract manufacturing companies play a pivotal role in ensuring that the production processes meet the regulatory requirements set by health authorities.

These companies are well-versed in navigating the complex landscape of pharmaceutical regulations. From Good Manufacturing Practice (GMP) to quality control and documentation, API contract manufacturers such as Akums Drugs & Pharmaceuticals Ltd are adept at adhering to the industry's stringent standards. This expertise is invaluable in securing regulatory approvals for the final drug product.

Collaborative Partnerships for Success

The relationship between pharmaceutical companies and API contract manufacturers is not just transactional; it is a partnership built on trust and collaboration. Communication is key to ensuring that both parties are aligned on quality standards, timelines, and any potential challenges that may arise during the manufacturing process.

This collaborative approach extends to research and development as well. API contract manufacturers often work closely with pharmaceutical companies in the early stages of drug development, providing valuable insights into the feasibility and scalability of manufacturing processes. This partnership fosters innovation and accelerates the time-to-market for new medications.

Conclusion

The journey from raw material APIs to the medicine you take involves a symphony of processes, with API contract manufacturers playing a crucial role in orchestrating this intricate dance. The quality, expertise, and flexibility they bring to the table are indispensable in ensuring that pharmaceuticals are not just produced but are produced with the utmost precision and compliance.

So, the next time you take your prescribed medication, remember the unsung heroes behind the scenes – the API contract manufacturers like Akums – who contribute significantly to making your healthcare experience safe and effective. Their commitment to excellence ensures that the pills you rely on are not just a mix of chemicals but a result of a meticulous and collaborative effort to improve lives.

[octanexlabsin]

Innovating for a Better Tomorrow: As a leading player in chemical synthesis, we serve Pharma, Agro, Fine and Specialty Chemicals, CRO, and CDMO industries with precision and expertise. Our custom development and CRAMS offerings enable global partnerships that consistently uphold quality. Committed to progress, we aim to enhance lives through unparalleled research and production.

[chemxpert]

Your Ultimate Partner in Medicine Manufacturing and Supply Chain Excellence

Chemxpert Database empowers pharmaceutical professionals by offering extensive insights into medicine manufacturing, including connections with top China pharmaceutical companies. With a focus on sterile manufacturing and rigorous pharmaceutical testing, Chemxpert streamlines supply chain management in the pharmaceutical industry, ensuring quality and compliance at every stage. Trusted for its robust data, Chemxpert Database is an invaluable tool for enhancing manufacturing efficiency and maintaining high standards across global pharmaceutical operations.

[sauravchemicals]

Explore unparalleled pharmaceutical solutions at Saurav Chemicals, a leading innovator in Contract API Manufacturing.

[trendsofmarket]

Analysis of Pharmaceutical Contract Manufacturing and Research Services Market Outlook and Forecasts by Top Manufacturers, Production, Consumption, Trade Statistics, and Growth Analysis

Research Nester assesses the growth and market size of the global pharmaceutical contract manufacturing and research services market which is anticipated to account for the rising generics demand, increased pharmaceutical R&D spending, and contract manufacturing and research services investments in sophisticated manufacturing technologies.

Request Report Sample@

Research Nester’s recent market research analysis on “Pharmaceutical Contract Manufacturing and Research Services Market: Global Demand Analysis & Opportunity Outlook 2037” delivers a detailed competitor analysis and an overview of the global pharmaceutical contract manufacturing and research servicesmarket in terms of market segmentation by service, end user and by region.

Growing Demand for Biological Therapies to Promote Global Market Share of Pharmaceutical Contract Manufacturing and Research Services

The pharmaceutical contract manufacturing and research services business is expanding due to the expiring patents of certain drugs. While the branded pharmaceutical sector has suffered huge revenue and volume losses due to patent expiration, numerous new, less expensive generic alternatives are now entering the pharmaceutical contract manufacturing and research services marketplaces. A promising indication for the expansion of the pharmaceutical contract manufacturing and research services market over the projection period is the fact that generic companies are outsourcing their production to these services.

Access our detailed report at:

Some of the major growth factors and challenges that are associated with the global pharmaceutical contract manufacturing and research servicesmarket are:

Growth Drivers:

SMEs' Budgetary Restrictions

Commercial Success of Biologicals For Clinical Applications

Challenges:

The primary hindrance to the growth of this market is the presence of sizable pharmaceutical corporations with in-house medication manufacturing capabilities. These companies develop their candidate drugs, conduct internal studies, and conduct clinical trials. Many companies are steadily inclined to boost their manufacturing capacity and no longer rely on outsourced services to meet the global demand for pharmaceuticals.

By service, the global pharmaceutical contract manufacturing and research servicesmarket is segmented into manufacturing and research. The manufacturing segment is to register a significant CAGR during the forecast period. The increasing demand for vaccines and biosimilars is one of the main drivers of the segment's growth. The increase in companies opting to outsource the manufacturing of pharmaceutical finished goods, clinical trial materials, and active pharmaceutical ingredients (APIs) explains the profitable growth rate.

By region, the Europe pharmaceutical contract manufacturing and research services market is expected to register rapid revenue CAGR by the end of 2037. Increased funding for pharmaceutical R&D, strong intellectual property laws, shifting demographics, and a higher danger of epidemics are a few of the causes of this expansion. Furthermore, according to the European Commission, half of the pharmaceutical imports into the world's fastest-growing markets come from Europe.

This report also provides the existing competitive scenario of some of the key players of the global pharmaceutical contract manufacturing and research services market which includes company profiling of AbbVie, Recipharm AB, Baxter BioPharma, Dalton Pharma Services, Thermo Fisher Scientific Inc., Piramal Pharma Solutions, Jubilant Pharmova Limited, Samsung Biologics and others.

Request for customization @

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

[shobhaalss]

Bilastine API Manufacturers in india

Bilastine is an antihistamine used to treat conditions like allergies and chronic urticaria (hives). Several pharmaceutical manufacturers in India produce Bilastine API (Active Pharmaceutical Ingredient). Some of the prominent manufacturers that supply Bilastine API in India include:

1. Hetero Drugs

Overview: Hetero is one of India's largest pharmaceutical companies and a significant player in the generic API sector.

Specialization: They manufacture a wide range of APIs, including Bilastine, for domestic and international markets.

Website: www.heterodrugs.com

2.Shobha Lifesciences 

Overview: Shobha lifesciences is a global player with a strong portfolio of APIs, including those used for allergy treatments.

Specialization: Known for producing generic drugs and APIs, including antihistamines like Bilastine.

Website: www.Shobhalifesciences.com  

3. Cipla Ltd.

Overview: Cipla is one of India's leading pharmaceutical companies and has a robust API manufacturing capability.

Specialization: Cipla manufactures a range of APIs, including for the treatment of allergic conditions.

Website: www.cipla.com

4. Granules India

Overview: Granules India is a key player in the Indian pharmaceutical industry, with a focus on API production.

Specialization: Known for producing high-quality generic APIs, including antihistamines.

Website: www.granulesindia.com

5. Mylan Laboratories (now Viatris)

Overview: Mylan, now known as Viatris, is a leading global pharmaceutical company with a strong presence in India.

Specialization: The company manufactures a wide array of APIs and generic medications.

Website: www.mylan.in

6. Zydus Cadila

Overview: Zydus Cadila is a major pharmaceutical company in India, involved in the manufacturing of both finished dosage forms and APIs.

Specialization: It offers a broad range of APIs, including antihistamines like Bilastine.

Website: www.zyduscadila.com

7. Sun Pharmaceutical Industries

Overview: Sun Pharma is one of the largest pharmaceutical companies globally, and they produce a wide range of APIs.

Specialization: The company manufactures high-quality APIs and is involved in research and development for generic drugs.

Website: www.sunpharma.com

8. Intas Pharmaceuticals

Overview: Intas Pharmaceuticals is a leading pharmaceutical manufacturer in India that specializes in APIs and generic medicines.

Specialization: Known for producing a variety of antihistamines and other APIs.

Website: www.intaspharma.com

9. Lupin Pharmaceuticals

Overview: Lupin is a global pharmaceutical company, and it is involved in the manufacture of APIs for a wide range of therapeutic areas.

Specialization: Known for its expertise in the production of generic APIs.

Website: www.lupin.com

10. AstraZeneca India

Overview: While AstraZeneca is a global pharmaceutical company, they have a significant presence in India and produce several APIs, including antihistamines.

Specialization: Primarily involved in innovative medicines but also engaged in API manufacturing for certain therapeutic areas.

Website: www.astrazeneca.com

11. Vee Excel Drugs & Pharmaceuticals

Overview: Vee Excel is an Indian manufacturer that specializes in APIs and contract manufacturing for several therapeutic areas, including allergy treatments.

Specialization: They produce a variety of APIs, including Bilastine.

Website: www.veeexcel.com

These manufacturers produce Bilastine API either in bulk or in cooperation with international pharmaceutical companies. If you’re looking for a specific supplier or details on pricing, regulatory compliance, or distribution, contacting the manufacturers directly through their business development or sales departments is recommended.